SG/CALL/VERTEX PHARMACEUTICALS/400/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 03:45:11 2024-07-05 pm EDT | ||
| 8.86 EUR | +3.14% |
|
| Current month | -1.23% | ||
| 1 month | -11.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 8.86 | +3.14% |
| 24-07-04 | 8.59 | -0.23% |
| 24-07-03 | 8.61 | -4.86% |
| 24-07-02 | 9.05 | +0.78% |
| 24-07-01 | 8.98 | +0.11% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SV296V |
| ISIN | DE000SV296V4 |
| Date issued | 2023-04-12 |
| Strike | 400 $ |
| Maturity | 2025-01-17 (195 Days) |
| Parity | 10 : 1 |
| Emission price | 3.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.25 € |
|---|---|
| Lowest since issue | 2.97 € |
| Spread | 0.07 € |
| Spread % | 0.78% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
